McKesson Corporation’s Stock Price Takes a Hit, Plunges 9.90% to $514.75

McKesson Corporation (MCK)

514.75 USD -56.53 (-9.90%) Volume: 3.0M

McKesson Corporation’s stock price stands at 514.75 USD, experiencing a significant drop of 9.90% this trading session with a trading volume of 3.0M, yet showcasing a year-to-date increase of 11.18%, highlighting its volatile yet promising performance.

Latest developments on McKesson Corporation

Today, McKesson Corp stock price experienced movements following the drug distributor’s announcement of forecasting Q2 profit below estimates. Despite this, the company reaffirmed its Fiscal 2025 Adjusted EPS Guidance, which may have contributed to McKesson Corp stock outperforming competitors on a strong trading day. Additionally, the recent news of Rexall’s U.S. owner selling the pharmacy chain to Canadian private equity firm Birch Hill may have also impacted investor sentiment. McKesson’s decision to sell Rexall and Well.ca to Birch Hill has drawn attention to the company’s strategic moves in the market, with analysts closely monitoring the options activity to decipher the big picture for the future.

McKesson Corporation on Smartkarma

Analysts on Smartkarma, like Baptista Research, are bullish on Mckesson Corp, a healthcare company. In their recent report titled “McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers”, they highlighted the company’s strong financial performance in the Fourth Quarter Fiscal 2024. Mckesson Corp saw a 12% increase in consolidated revenue, reaching $309 billion, and a 6% rise in adjusted earnings per diluted share to $27.44. The company’s growth was attributed to its differentiated portfolio of assets, innovative solutions, and commitment to quality and operational excellence.

A look at McKesson Corporation Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

McKesson Corp, a company that distributes pharmaceuticals and medical supplies, has received mixed scores in various factors that determine its long-term outlook. While it scored high in resilience and growth, indicating its ability to withstand challenges and potential for expansion, it scored lower in value and momentum. The company’s dividend score falls in the middle range. This suggests that McKesson Corp may have strong potential for growth and resilience in the long term, but investors may need to carefully consider its overall value and momentum in their investment decisions.

Overall, McKesson Corp’s Smart Scores paint a picture of a company with solid growth prospects and a strong ability to weather market fluctuations. With a focus on distributing pharmaceuticals and developing software for the healthcare industry, the company has positioned itself as a key player in the North American market. Investors looking for a company with a strong growth trajectory and resilience may find McKesson Corp an attractive option, despite some potential concerns about its overall value and momentum.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma